Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Labetalol [INN:BAN]
RN: 36894-69-6
UNII: R5H8897N95
InChIKey: SGUAFYQXFOLMHL-UHFFFAOYSA-N

Note

  • A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.

Molecular Formula

  • C19-H24-N2-O3

Molecular Weight

  • 328.4096
 

Classification Codes

  • Adrenergic Agents
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Adrenergic Antagonists
  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Autonomic Agents
  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Human Data
  • Neurotransmitter Agents
  • Peripheral Nervous System Agents
  • Sympathomimetics

Names and Synonyms

Name of Substance

  • Labetalol
  • Labetalol [INN:BAN]

MeSH Heading

  • Labetalol

Synonyms

  • 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide
  • 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
  • 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
  • AH 5158
  • Albetol
  • EC 253-258-3
  • EINECS 253-258-3
  • HSDB 6537
  • Ibidomide
  • Labetalol
  • Labetalolum
  • Labetalolum [INN-Latin]
  • Labetolol
  • SCH 15719W
  • UNII-R5H8897N95

Systematic Names

  • Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-
  • Labetalol

Registry Numbers

CAS Registry Number

  • 36894-69-6

FDA UNII

  • R5H8897N95

System Generated Number

  • 0036894696

Structure Descriptors

InChI

1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)

InChIKey

SGUAFYQXFOLMHL-UHFFFAOYSA-N

Smiles

CC(CCc1ccccc1)NCC(c2ccc(c(c2)C(=O)N)O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo oral 240mg/kg/14D (240mg/kg) PERIPHERAL NERVE AND SENSATION: PARESTHESIS British Medical Journal. Vol. 1, Pg. 580, 1978.
man TDLo oral 8571mg/kg/D (8571mg/kg) BEHAVIORAL: CHANGES IN PSYCHOPHYSIOLOGICAL TESTS British Medical Journal. Vol. 282, Pg. 1824, 1981.
mouse LD50 intravenous 97500ug/kg (97.5mg/kg)   United States Patent Document. Vol. #5326774,
mouse LD50 oral 660mg/kg (660mg/kg)   United States Patent Document. Vol. #5326774,
rat LD50 intravenous > 50mg/kg (50mg/kg)   Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 229, 1979.
rat LD50 oral > 2gm/kg (2000mg/kg)   Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, Pg. 229, 1979.
women TDLo oral 2mg/kg (2mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Annals of Internal Medicine. Vol. 104, Pg. 729, 1986.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 188 deg C   EXP
log P (octanol-water) 3.09 (none)   EXP
Water Solubility 117 mg/L 25 EXP
Vapor Pressure 1.10E-13 mm Hg 25 EST
Henry's Law Constant 6.63E-19 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 1.51E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.